Recent Advances in Gene Therapy for Skin Barrier Dysfunction

Strategic Insights -

Researchers from Cathay General Hospital in Taipei, Taiwan, have outlined the pivotal role of skin barrier dysfunction in inflammatory skin diseases such as atopic dermatitis and psoriasis. A comprehensive review of recent advances in the transcriptional and post-transcriptional regulation of key skin barrier-related genes, including FLG, LOR, CLDN1, AQP3, and IVL, has been published in Biomedicine & Pharmacotherapy. The study highlights the potential of barrier-centric, gene-targeted approaches in managing chronic dermatoses.

Key Takeaways:

  • Intrinsic genetic variations and immune-mediated cytokine pathways, particularly the T helper 2 and T helper 17 axes, disrupt the epidermal defense system in inflammatory skin diseases.
  • Emerging therapeutic strategies targeting skin barrier restoration include natural compounds, biologic agents, and gene modulation technologies such as small interfering RNA, antisense oligonucleotides, and histone deacetylase inhibitors.
  • The gut-skin axis and microbial metabolites impact epidermal gene expression, and artificial intelligence and multi-omic integration can drive biomarker discovery and enable precision dermatology.
  • Skin barrier dysfunction is a key driver of atopic dermatitis and psoriasis, and targeting its transcriptional and post-transcriptional regulation can lead to improved disease management.
  • Researchers from Cathay General Hospital, including Yang Che-Wen, Feng-Ling Lin, Kun-Hung Chen, Yu-Ping Cheng, Yu-Che Cheng, and Jiun-Wen Guo, have contributed to the study.

Statistics:

  • The number of people affected by atopic dermatitis worldwide is estimated to be approximately 15-20% of the global population (Source: Biomedicine & Pharmacotherapy).
  • Psoriasis affects around 125 million people worldwide, with the majority being Asian (Source: Biomedicine & Pharmacotherapy).
  • The Alpha-7 nicotinic acetylcholine receptor (α7AChR) has been shown to play a crucial role in skin barrier dysfunction in atopic dermatitis and psoriasis (Source: Transcriptional dysregulation of skin barrier genes in atopic dermatitis and psoriasis: Mechanistic insights and emerging therapeutic strategies).
  • The gut-skin axis is characterized by the presence of a unique population of gut-associated lymphoid tissue (GALT) that secretes cytokines influencing skin barrier function (Source: Biomedicine & Pharmacotherapy).
  • The study highlights the potential of using advanced gene modulation technologies, such as small interfering RNA, to restore skin barrier function and treat chronic dermatoses (Source: Transcriptional dysregulation of skin barrier genes in atopic dermatitis and psoriasis: Mechanistic insights and emerging therapeutic strategies).

Sources:

  • Transcriptional dysregulation of skin barrier genes in atopic dermatitis and psoriasis: Mechanistic insights and emerging therapeutic strategies. Biomedicine & Pharmacotherapy, 2025;191:118508.
  • NewsRx. Reports from Cathay General Hospital Describe Recent Advances in Gene Therapy (Transcriptional dysregulation of skin barrier genes in atopic dermatitis and psoriasis: Mechanistic insights and emerging therapeutic strategies). Gene Therapy Weekly. September 18, 2025; p 310.